Se ha denunciado esta presentación.
Utilizamos tu perfil de LinkedIn y tus datos de actividad para personalizar los anuncios y mostrarte publicidad más relevante. Puedes cambiar tus preferencias de publicidad en cualquier momento.

Merck Loses Appeal in Antibiotic Cubicin Patent Case

90 visualizaciones

Publicado el

In a new litigation in the patent and trademark arena, the federal appeals court invalidated Merc’s four of 5 patents pertaining to Cubicin, a drug used to treat various infections in human body. With this judgment, Merck & Co’s four of five patents for the antibiotic Cubicin will be invalidated which it got through its acquisition of Cubist Pharmaceuticals Inc. The move will offer competitors with a chance to come-up with low-cost, generic version of the drug which was making $1 bn yearly in the United States.

Publicado en: Derecho
  • Sé el primero en comentar

  • Sé el primero en recomendar esto

×